| Autor: |
Saori Murata, Morio Nakamura, Kai Sugihara, Tetsuya Sakai, Kota Ishioka, Saeko Takahashi, Shinji Sasada, Hiroyuki Yasuda, Koichi Fukunaga |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Asian Pacific Journal of Cancer Care, Vol 7, Iss 1, Pp 191-196 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2588-3682 |
| DOI: |
10.31557/apjcc.2022.7.1.191-196 |
| Popis: |
Background: The neutrophil-to-lymphocyte ratio (NLR) is recognized as a predictive and prognostic biomarker in various malignancies. We investigated the utility of the NLR in patients with advanced non-small cell lung cancer (NSCLC) in the early phase of nivolumab monotherapy. Methods: Thirty-one patients with advanced NSCLC were treated with nivolumab monotherapy from January 2016 to August 2017. They underwent the first response evaluation 8.3±3.3 weeks (mean±SD) after 3.8±1.8 times of administration. The NLR values at baseline (NLR/base) and at the first response evaluation (NLR/1st) were analyzed to evaluate for the association between NLR and the following parameters: treatment response, progression-free survival (PFS) and overall survival (OS). Results: The median follow-up period was 467 days (range: 38-1903 days). NLR/1st in the disease control (DC) group (n=21, median: 4.36, range: 0.82-11.3) was significantly lower than that in the progression disease (PD) group (n=10, median: 11.91, range 2.04-31.00) (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
